Yong-Lin Qin1, Gang Deng, Tian-Xiao Li, Weiping Wang, Gao-Jun Teng. 1. Department of Radiology, Section of Interventional Radiology and Vascular Surgery, Zhongda Hospital, Medical School, Southeast University, Nanjing 210009, China.
Abstract
OBJECTIVES: This study sought to evaluate the early and long-term effect of thoracic endovascular aortic repair (TEVAR) on type-B acute aortic dissection (AAD). BACKGROUND: Uncomplicated type-B AAD is generally treated with medical management; complicated dissections require surgery or TEVAR. Studies have demonstrated that long-term outcomes with medical management are suboptimal. Therefore, we sought to determine the long-term effect of TEVAR compared with medical management alone on type-B AAD. METHODS: From January 2004 to May 2008, 193 consecutive patients in 2 hospitals were treated and retrospectively placed into 1 of 2 groups: 1) the TEVAR group-type-B AAD treated with TEVAR and antihypertensive medications (n = 152); and the 2) medicine group-uncomplicated type-B AAD treated medically alone (n = 41). All TEVAR procedures were performed in the acute phase. RESULTS: There were no significant differences in demographics, comorbidity profiles, or early events between groups. The cumulative freedom from all late adverse events at 1, 3, and 5 years was 97%, 89%, and 67% in the TEVAR group and 97%, 63%, and 34% in the medicine group. Log-rank tests showed that medically treated patients had more late adverse events than TEVAR-treated patients did (p = 0.003). The 5-year cumulative survival rate from all-cause death was not significantly different between the 2 groups. CONCLUSIONS: Patients with type-B AAD treated with TEVAR experienced fewer late adverse events than those treated with medical management, but there was no significant difference among the groups in 5-year mortality rates. Further studies of longer-term survival rates are needed to determine whether TEVAR could be an effective treatment for type-B AAD.
OBJECTIVES: This study sought to evaluate the early and long-term effect of thoracic endovascular aortic repair (TEVAR) on type-B acute aortic dissection (AAD). BACKGROUND: Uncomplicated type-B AAD is generally treated with medical management; complicated dissections require surgery or TEVAR. Studies have demonstrated that long-term outcomes with medical management are suboptimal. Therefore, we sought to determine the long-term effect of TEVAR compared with medical management alone on type-B AAD. METHODS: From January 2004 to May 2008, 193 consecutive patients in 2 hospitals were treated and retrospectively placed into 1 of 2 groups: 1) the TEVAR group-type-B AAD treated with TEVAR and antihypertensive medications (n = 152); and the 2) medicine group-uncomplicated type-B AAD treated medically alone (n = 41). All TEVAR procedures were performed in the acute phase. RESULTS: There were no significant differences in demographics, comorbidity profiles, or early events between groups. The cumulative freedom from all late adverse events at 1, 3, and 5 years was 97%, 89%, and 67% in the TEVAR group and 97%, 63%, and 34% in the medicine group. Log-rank tests showed that medically treated patients had more late adverse events than TEVAR-treated patients did (p = 0.003). The 5-year cumulative survival rate from all-cause death was not significantly different between the 2 groups. CONCLUSIONS:Patients with type-B AAD treated with TEVAR experienced fewer late adverse events than those treated with medical management, but there was no significant difference among the groups in 5-year mortality rates. Further studies of longer-term survival rates are needed to determine whether TEVAR could be an effective treatment for type-B AAD.
Authors: Konstantinos G Moulakakis; Spyridon N Mylonas; Ilias Dalainas; John Kakisis; Thomas Kotsis; Christos D Liapis Journal: Ann Cardiothorac Surg Date: 2014-05
Authors: María Elena Arnáiz-García; José María González-Santos; Ana María Arnáiz-García; Javier Arnáiz Journal: J Thorac Dis Date: 2017-10 Impact factor: 2.895
Authors: Anna M Sailer; Sander M J van Kuijk; Patricia J Nelemans; Anne S Chin; Aya Kino; Mark Huininga; Johanna Schmidt; Gabriel Mistelbauer; Kathrin Bäumler; Peter Chiu; Michael P Fischbein; Michael D Dake; D Craig Miller; Geert Willem H Schurink; Dominik Fleischmann Journal: Circ Cardiovasc Imaging Date: 2017-04 Impact factor: 7.792
Authors: Liana D Wobben; Marina Codari; Gabriel Mistelbauer; Antonio Pepe; Kai Higashigaito; Lewis D Hahn; Domenico Mastrodicasa; Valery L Turner; Virginia Hinostroza; Kathrin Baumler; Michael P Fischbein; Dominik Fleischmann; Martin J Willemink Journal: Annu Int Conf IEEE Eng Med Biol Soc Date: 2021-11